Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(002399),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002399 Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.

Closed 12-22 15:00:00

11.79

-0.03

-0.25%

High11.85	Low11.71	Vol2.39M
Open11.83	D1 Closing11.82	Amplitude1.18%
Mkt Cap17.30B	Tradable Cap14.70B	Total Shares1.47B
T/O28.19M	T/O Rate0.19%	Tradable Shares1.25B
P/B1.4	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.","latestPrice":11.79,"timestamp":1766387013000,"preClose":11.82,"halted":0,"volume":2390720,"delay":0,"changeRate":-0.0025,"floatShares":1247000000,"shares":1467000000,"eps":0.2864,"marketStatus":"Closed","change":-0.03,"latestTime":"12-22 15:00:00","open":11.83,"high":11.85,"low":11.71,"amount":28191200,"amplitude":0.0118,"askPrice":11.8,"askSize":26,"bidPrice":11.79,"bidSize":54,"shortable":0,"etf":0,"ttmEps":0.2864,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"adjPreClose":11.82,"symbolType":"stock","openAndCloseTimeList":[[1766367000000,1766374200000],[1766379600000,1766386800000]],"highLimit":13,"lowLimit":10.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"isCdr":false,"pbRate":1.4,"roa":"--","peRate":41.166201,"roe":"4.51%","epsLYR":0.4408,"committee":-0.215165,"marketValue":17299000000,"turnoverRate":0.0019,"status":1,"hkstockBrief":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"HEPALINK","latestPrice":5.22,"timestamp":1766390890009,"preClose":5.24,"halted":0,"volume":400500,"delay":0,"premium":"-59.99"},"floatMarketCap":14705000000},"requestUrl":"/m/hq/s/002399/wiki","defaultTab":"wiki","newsList":[{"id":"2591731983","title":"Shenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2591731983","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591731983?lang=en_us&edition=fundamental","pubTime":"2025-12-16 18:37","pubTimestamp":1765881457,"startTime":"0","endTime":"0","summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the Strategy Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the Strategy and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbQZ3vH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","002399","BK0070"],"gpt_icon":0},{"id":"2591983227","title":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591983227?lang=en_us&edition=fundamental","pubTime":"2025-12-16 18:35","pubTimestamp":1765881335,"startTime":"0","endTime":"0","summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. held its first extraordinary general meeting of 2025 on December 16. Shareholders approved proposals including the abolition of the Supervisory Committee, amendments to the Articles, amendments to related rules of procedures and certain internal corporate governance measures, and the election of an independent non-executive director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL5rBljV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0239","BK0188","002399"],"gpt_icon":0},{"id":"1174356071","title":"60% Discount to A-Share Price: Is Hepalink (09989) Signaling a Bottom as Heparin Exits Downturn Cycle?","url":"https://stock-news.laohu8.com/highlight/detail?id=1174356071","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174356071?lang=en_us&edition=fundamental","pubTime":"2025-12-06 14:26","pubTimestamp":1765002387,"startTime":"0","endTime":"0","summary":"On October 30, 2025, Hepalink (09989) released its Q3 financial report, showing revenue of RMB 4.194 billion for the first three quarters, up 3.09% YoY, while net profit attributable to shareholders...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","09989","159982","399300","BK0239","BK0188","BK1191","002399"],"gpt_icon":0},{"id":"2585465362","title":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Date for First Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585465362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585465362?lang=en_us&edition=fundamental","pubTime":"2025-11-24 18:34","pubTimestamp":1763980459,"startTime":"0","endTime":"0","summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has announced that it will hold its first extraordinary general meeting of 2025 on December 16. During the meeting, shareholders will vote on several key proposals, including the proposed abolition of the Supervisory Committee, amendments to the company's Articles of Association and related rules of procedures, amendments to certain internal corporate governance measures, and the election of an independent non-executive director. The meeting will take place at L'Hermitage Hotel in Shenzhen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Servic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL62cp51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002399","BK0188","BK0070"],"gpt_icon":0},{"id":"1102043483","title":"HEPALINK (09989) Proposes Election of Pu Hong as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1102043483","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102043483?lang=en_us&edition=fundamental","pubTime":"2025-11-24 18:34","pubTimestamp":1763980450,"startTime":"0","endTime":"0","summary":"HEPALINK (09989) announced that the board has proposed the election of Pu Hong as an independent non-executive director, subject to approval by shareholders at an extraordinary general meeting.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0188","BK1191","09989","BK0239","002399"],"gpt_icon":0},{"id":"1196017394","title":"HEPALINK Reports Net Profit of Approximately 553 Million Yuan in First Three Quarters","url":"https://stock-news.laohu8.com/highlight/detail?id=1196017394","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196017394?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:31","pubTimestamp":1761816714,"startTime":"0","endTime":"0","summary":"On October 30, HEPALINK (09989.HK) announced on the Hong Kong Stock Exchange that its revenue for the first three quarters of 2025 reached approximately 4.194 billion yuan, a year-on-year increase of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0188","002399","BK0239","09989","BK0070"],"gpt_icon":0},{"id":"2579974841","title":"Shenzhen Hepalink Pharmaceutical - Qtrly Net Profit Attributable RMB131.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2579974841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579974841?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:06","pubTimestamp":1761815178,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0070","BK0188","002399"],"gpt_icon":0},{"id":"2579019748","title":"Shenzhen Hepalink Pharmaceutical Group Co Ltd: Qtrly Operating Revenue RMB 1.38 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2579019748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579019748?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:06","pubTimestamp":1761815178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB12Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0188","002399","BK0070"],"gpt_icon":0},{"id":"1106330470","title":"HEPALINK (09989) Announces Interim Results with Net Profit Attributable to Parent of Approximately RMB 422 Million, Down 36.4% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1106330470","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106330470?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:04","pubTimestamp":1756458267,"startTime":"0","endTime":"0","summary":"HEPALINK (09989) announced its interim results for 2025, with revenue of approximately RMB 2.791 billion, down 1.3% year-on-year. Net profit attributable to shareholders of the parent company reached...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","09989","002399","BK0239","BK0070","BK1191"],"gpt_icon":0},{"id":"2563177390","title":"Shenzhen Hepalink Reports 1.3% Decline in Revenue and 36.4% Drop in Profit for H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2563177390","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563177390?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:43","pubTimestamp":1756457023,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL8wgHTw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002399"],"gpt_icon":0},{"id":"2563299017","title":"Shenzhen Hepalink Pharmaceutical - Hy REV RMB2.79 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563299017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563299017?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:40","pubTimestamp":1756456848,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL05X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002399","BK0188","BK0239","BK0070"],"gpt_icon":0},{"id":"2552465683","title":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2552465683","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552465683?lang=en_us&edition=fundamental","pubTime":"2025-07-18 17:02","pubTimestamp":1752829341,"startTime":"0","endTime":"0","summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDLc7YL1H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0239","BK0188","002399"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","stockEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.019},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0317},{"period":"1year","weight":0.0655},{"period":"ytd","weight":0.1263}],"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"146729万元","compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"survey":"　　深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠、依诺肝素钠原料药、大分子药物CDMO服务。","serverTime":1766437446378,"listedPrice":148,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(002399),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(002399) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.,002399,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票老虎,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票老虎国际,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.行情,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票行情,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股价,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股市,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票价格,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票交易,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票购买,Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(002399),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.(002399) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction